Xbiome, an AI Company, Completes B+ Round for Microbiome Trials

Shenzhen Xbiome, which uses AI to develop microbiome products, raised "tens of million dollars" in a Series B+ round to support development of its gut bacteria therapies. The company is ready to start tests in 2021 of fecal microbiota transplantation (FMT) capsules that treat autism and graft-versus-host disease (GvHD). The programs have already started China investigator-initiated trials. The B+ round was led by Primavera Capital and Gaorong Capital, with existing investors Legend Capital and 5Y (formerly Morningside Venture) participating. More details.... Share this with colleagues: // //